NICE says ‘yes’ to new blood cancer drug
11 March 2015 | By Roche
New option for patients as NICE accepts Gazyvaro® (obinutuzumab) for treatment of most common adult leukaemia...
List view / Grid view
News
Big Pharma drives innovation in pain therapy development, despite declining patent applications, says GBI Research
10 March 2015 | By GBI Research
Patent applications for novel pain therapeutics declined steadily in number from 4,970 in 2008 to 3,492 in 2012, an average annual decrease of 8%, as limited understanding of pain pathophysiology continues to hinder drug development in this arena, says business intelligence provider GBI Research...
New data shows blood glucose, CV risk factors and quality of life outcomes improvement with Saxenda®
9 March 2015 | By Novo Nordisk
New data from the phase 3a SCALE™ Obesity and Prediabetes trial were presented at The Endocrine Society’s 97th Annual Meeting (ENDO), showing that adults with obesity or who are overweight with comorbidities who had lost ≥5% of their body weight at 56 weeks (ie weight loss responders), demonstrated greater improvements…
Gilead receives approval from the Scottish Medicines Consortium for use of zydelig® (idelalisib) for the treatment of chronic lymphocytic leukaemia
9 March 2015 | By Gilead Sciences
New oral treatment for Chronic Lymphocytic Leukaemia now approved for use within NHS Scotland...
AbbVie acquires Pharmacyclics to help secure future cash flows as Humira biosimilars loom
6 March 2015 | By GlobalData
“AbbVie’s acquisition of Pharmacyclics (PCYC), valued at $21 billion, will help the company alleviate its dependency on Humira, which accounted for 62% of its total revenues in 2014, up from 57% in 2013..."
AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV
6 March 2015 | By AOP Orphan
AOP Orphan Pharmaceuticals AG reported the completion of recruitment for its phase III trial PROUD-PV to support global licensure of Ropeginterferon alfa 2b (AOP2014/P1101), a novel, long-acting, mono-pegylated Interferon for the treatment of Polycythemia Vera...
Getting the sums right
5 March 2015 | By NHS Confederation
Personal health budgets are “complex” to introduce but the financial challenges of implementing them can be minimised if providers and commissioners work together, according to a briefing paper published ahead of their expansion from next month...
Rottendorf Pharmaceuticals continues growth with multiple new deals with top 5 pharma companies for solid dose development and manufacturing
5 March 2015 | By Rottendorf Pharmaceuticals
Positioned as top 20 contract development and manufacturing organization recognized by five 2015 CMO leadership awards...
Chamaeleo Pharma appoints Han Van ‘t Klooster as Vice President of Commercial Operations
5 March 2015 | By Chamaeleo Pharma
Chamaeleo Pharma NV, a Belgium-based oncology company, announced that Han Van ‘t Klooster has joined Chamaeleo as Vice President of Commercial Operations...
Bristol-Myers Squibb announces U.S. FDA approval of an additional indication for Opdivo (nivolumab)
5 March 2015 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced an approval of an additional indication for Opdivo (nivolumab) by the U.S. Food and Drug Administration...
European CHMP issues positive opinion for a label update of Lundbeck’s Brintellix® (vortioxetine)
5 March 2015 | By H. Lundbeck A/S
Lundbeck today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for a Type-II Variation related to the update of the European summary of the product characteristics (SmPC) for Brintellix...
World’s largest and fully integrated healthcare exhibition tHIS announces further expansion
4 March 2015 | By Reed Sinopharm Exhibitions
The Health Industry Summit, EXPO and Congress (tHIS) held in May in Shanghai announced further increases in size to reach 280,000sqm ahead of its grand opening...
Boehringer Ingelheim submits applications for approval of idarucizumab to EMA, FDA and Health Canada
4 March 2015 | By Boehringer Ingelheim
Boehringer Ingelheim announces that idarucizumab has been submitted for approval of marketing authorisation to the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA) and Health Canada...
Roche Annual General Meeting 2015
4 March 2015 | By Roche
Roche announced that its Ordinary Annual General Meeting has voted in favour of all of the Board of Directors’ proposals...
BIOTRONIK BIOLUX P-I clinical study published in Journal of Endovascular Therapy
4 March 2015 | By BIOTRONIK
Results demonstrate advantage of BIOTRONIK's Passeo-18 Lux drug-coated balloon catheter for the treatment of superficial femoral and popliteal artery disease...
